PARK CITY, Utah — Stage one of the phase 3 DIAMOND trial of OCS-01, a high-concentration dexamethasone eye drop for diabetic macular edema, showed promising safety and efficacy outcomes. Stage two of the trial is underway.
“OCS-01 has a really exciting potential to fill that glaring, almost unspoken treatment gap in retina — the noninvasive approach,” Courtney Crawford, MD, said at Clinical Trials at the Summit.
DIAMOND is a multicenter trial conducted at 39 U.S. and European sites. One hundred forty-eight patients were randomly assigned 2:1 to receive OCS-01 (Oculis) or